SOHO 2025 | Exploring strategies to optimize post-CAR-T outcomes in patients with ALL
In this video, Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, discusses the need to identify strategies to optimize post-CAR T-cell therapy outcomes in patients with acute lymphoblastic leukemia (ALL). Dr Shah hopes that integrating CAR T-cell therapy into earlier lines of treatment will simplify post-CAR-T management. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
As we integrate CAR T-cell therapy into earlier lines of therapy, one key question is, do we stop at the CAR? You know, you heard me say in the answer to my last question, we need to find out how to compartmentalize the therapy. We can’t have, you know, multiple years of therapy. Otherwise, we’re going to lose patients to adherence for toxicity, for a variety of different reasons...
As we integrate CAR T-cell therapy into earlier lines of therapy, one key question is, do we stop at the CAR? You know, you heard me say in the answer to my last question, we need to find out how to compartmentalize the therapy. We can’t have, you know, multiple years of therapy. Otherwise, we’re going to lose patients to adherence for toxicity, for a variety of different reasons. So I think that when we talk about post-CAR-T strategies, we have to come up with approaches that are viable. What do I mean by that? I think TKIs are viable. We have a favorable benefit-to-toxicity ratio there. It does look like in retrospective series that there’s a benefit for incorporating a TKI, particularly if it’s one they haven’t seen following CAR T-cell therapy. So there may be some benefit there. Transplant is a hard one. And I think we’re still learning and there may be certain very high-risk genotypes that benefit from that approach. But my hope is, as we integrate CAR-T into earlier lines of therapy, that the post-CAR-T question becomes an easier one to address and answer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
